Clinical trial
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed…
NCT00496132 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00496132 |
|---|---|
| Title | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Have Been Treated With a Purine Nucleoside Analogue-Containing Regimen |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | PRO131921 |
| Enrollment | 16 |
| Start date | Aug 27, 2007 |
| Primary completion | Jun 17, 2009 |
| Completion | Jun 17, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Jul 2, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: